Aktiesnakken — Juni 2013
-
, Dulaglutide. Dataene skræmmer os ikke, og vi ser ingen argumenter for, at Dulaglutide skulle være bedre end Victoza. Afgørende bliver dog resultatet at et studie, hvor de to produkter sammenlignes direkte. Dette resultat ventes i slutningen af 2013. Generelt mener vi, at markedets bekymring om risikoen for kræft i bygspytkirtlen ved brug af Victoza og bekymringer om konkurrence fra Dulaglutide er overgjorte. Vi anbefaler, at man udnytter den seneste svaghed i aktien til at samle op.
-
der er lukket for handel mashoufi
-
blev lukket i fredags
-
-
sorry jeg troede alt var lukket i fredags
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
